https://www.barrons.com/articles/regeneron-stock-price-fda-decision-eb4c0464
0
0
6/27/23 at 8:01pm
Organization
Barron's
Author
Josh Nathan-Kazis
The Food and Drug Administration rejected its application for approval of a new, higher-dose version of eye disease treatment Eylea.
Create an account
or login to join the discussion